United States Cancer Diagnostics Market Insights, 2031

Key Insights

• According to the research report, "USA Cancer Diagnostics Market Outlook, 2031," published by Bonafide Research, the USA Cancer Diagnostics Market was valued at more than 34.77 Billion in 2025.
• The U.S. cancer diagnostics landscape is undergoing a massive shift away from invasive tissue biopsies toward non-invasive liquid biopsy techniques and advanced biomarker profiling. High-throughput next-generation sequencing (NGS) and multi-cancer early detection (MCED) blood tests allow clinical teams to analyze circulating tumor DNA (ctDNA) and RNA fragments from a simple blood draw. This enables real-time monitoring of treatment efficacy, earlier detection of patient relapse, and precise companion diagnostic mapping for targeted therapies. Over 2,000,000 new cancer cases are diagnosed annually across the United States. More than 310,000 women and 2,800 men are diagnosed with breast cancer in the U.S. each year. Standard clinical reimbursement benchmarks for comprehensive next-generation sequencing assays hover around $2,989 per test, underscoring the high capital utilization per patient diagnostic profile.
• Artificial intelligence and machine learning algorithms are rapidly moving from clinical trial validation to routine diagnostic workflows across U.S. hospitals. Breakthroughs in spatial biology and AI-enhanced digital pathology are dramatically reducing diagnostic error rates in tissue interpretation while speeding up turnaround times. Furthermore, advanced imaging modalities such as spectral CT, low-dose mammography, and high-field functional MRI are integrating deep learning algorithms to detect micro-metastases and sub-visual lesion patterns long before physical symptoms appear. In U.S. clinical pathology workflows, assay kits and diagnostic reagents continue to comprise the dominant product volume, accounting for over 80% of total consumable product demand.

Market Outlook

• The future trajectory of U.S. cancer diagnostics is heavily anchored in decentralization, shifting diagnostic capabilities from centralized university hospital settings into community clinics, outpatient surgical centers, and reference laboratories. Key industry organizations driving clinical standards and advocacy such as the American Association for Cancer Research (AACR), the College of American Pathologists (CAP), and the American Cancer Society (ACS)are expanding guidelines to support broader community screening protocols. Major commercial innovators leading this ecosystem include Thermo Fisher Scientific, Illumina, Abbott Laboratories, Roche Diagnostics, Agilent Technologies, Exact Sciences, Danaher Corporation, and GE HealthCare.
• A major tailwind for the U.S. market outlook is the ongoing evolution of regulatory frameworks and payer policies toward early-detection technologies. Public health initiatives, coupled with streamlined U.S. FDA Breakthrough Device Designation pathways and favorable CMS (Centers for Medicare & Medicaid Services) reimbursement coverage, are lowering the barriers for commercial adoption of innovative molecular panels. As public and private payers increasingly recognize the long-term cost-effectiveness of detecting malignancies at Stage 0 or Stage I rather than managing late-stage care, diagnostic coverage expansion will remain a pivotal growth engine across all 50 states.

Market Dynamics

Driver: High prevalence of malignancy and demand for early intervention
The primary growth driver for the U.S. cancer diagnostics market is the surging incidence of malignant tumors combined with an aging domestic population. With over 2 million new clinical cancer diagnoses annually across the nation, healthcare delivery systems are under intense structural pressure to detect neoplasms at localized or pre-cancerous stages. Early intervention significantly improves 5-year relative survival rates and substantially reduces overall downstream oncology treatment costs for payers and patients.
Challenge: Complex reimbursement landscape and high capital requirements
The most significant headwind facing the U.S. market is the intricate regulatory and financial hurdle of securing broad, consistent insurance coverage and reimbursement for novel molecular tests. Diagnostic developers must establish robust, peer-reviewed clinical utility and analytical validity before major public payers such as Medicare and Medicaid or private health insurers assign permanent Current Procedural Terminology (CPT) codes and adequate payment rates. Furthermore, advanced diagnostic platforms, including automated Next-Generation Sequencing (NGS) systems and high-field digital pathology scanners, demand massive initial capital expenditures from clinical facilities.
Trend: Integration of AI-powered digital pathology & multi-cancer early detection (MCED)
A key trend reshaping the U.S. diagnostic ecosystem is the convergence of artificial intelligence (AI) with liquid biopsy and digital spatial biology platforms. Diagnostic providers are shifting from single-organ, tissue-heavy biopsies toward blood-based Multi-Cancer Early Detection (MCED) screening panels capable of identifying circulating tumor DNA (ctDNA) across dozens of cancer types simultaneously. Concurrently, pathologists are leveraging deep learning algorithms to automatically score histopathological slides, analyze tumor microenvironments, and identify microscopic spatial biomarkers with greater speed and accuracy.

Policies

• FDA In Vitro Diagnostic (IVD) Approval Pathways: Medical devices and diagnostic kits commercialized in the U.S. are regulated by the U.S. Food and Drug Administration (FDA) through pre-market clearance pathways primarily Premaket Notification 510(k), De Novo Classification, or Premarket Approval (PMA) based on the device's clinical risk categorization.
• Clinical Laboratory Improvement Amendments (CLIA) Certification: Managed across CMS, FDA, and CDC, CLIA regulations enforce strict federal quality standards for all clinical laboratories testing human specimens in the U.S. Facilities are categorized by test complexity (Waived, Moderate, or High Complexity) and must pass rigorous proficiency testing and operational audits.
• Regulation of Laboratory Developed Tests (LDTs): In vitro diagnostic tests designed, manufactured, and utilized within a single CLIA-certified laboratory (LDTs) fall under evolving FDA oversight frameworks, shifting LDT regulation closer to standardized medical device requirements and strict analytical validation protocols.

Segment Analysis

USA Cancer Diagnostics By Product Type
• The consumables and reagents segment is characterized by recurring demand for antibodies, molecular assay kits, staining reagents, nucleic acid extraction materials, and diagnostic probes used throughout cancer testing workflows. A distinctive feature of the U.S. market is the growing need for highly standardized, assay-specific consumables that can support reproducible results across hospital laboratories, reference testing facilities, and specialized oncology centers. The expansion of genomic profiling and biomarker-guided treatment is increasing the importance of reagents capable of detecting clinically relevant genetic alterations and protein expression patterns.
• The instruments segment includes molecular diagnostic analyzers, sequencing systems, pathology equipment, digital slide scanners, imaging systems, and biopsy-related devices used to identify and characterize malignant disease. A distinctive market trend in the United States is the transition from standalone diagnostic equipment toward connected, automated workflows that integrate specimen preparation, testing, image analysis, and laboratory information systems. Digital pathology scanners and advanced image-analysis software are helping laboratories digitize tissue slides, facilitate remote specialist review, and support collaboration between pathologists and oncology teams.

USA Cancer Diagnostics By Technology
• In vitro diagnostic (IVD) testing is a central component of the U.S. cancer diagnostics market because it enables the detection of cancer-associated biomarkers using blood, tissue, and other biological specimens. The segment encompasses polymerase chain reaction (PCR), next-generation sequencing (NGS), immunoassays, immunohistochemistry, in situ hybridization, and other molecular and cellular testing methods. A distinctive feature of the U.S. market is the increasing integration of molecular diagnostics into clinical decision-making, allowing physicians to identify tumor-specific alterations, distinguish biologically different cancers, and evaluate eligibility for targeted therapies. Companion diagnostics are particularly important because certain treatment decisions depend on identifying specific biomarkers before therapy begins. Another emerging area is the use of circulating tumor DNA and other blood-based biomarkers for selected diagnostic and monitoring applications.
• Anatomic pathology plays a fundamental role in confirming malignancy through the examination of tissue and cellular specimens. In the United States, this segment combines conventional histopathology and cytopathology with immunohistochemistry, special staining, tissue processing, and increasingly digital pathology-based analysis. Its distinctive value lies in connecting the microscopic appearance of a tumor with its biological characteristics, enabling pathologists to establish tumor type, assess differentiation, evaluate margins, and identify features relevant to prognosis and treatment selection. The adoption of digital slide scanning and computational image analysis is changing how pathology departments manage large specimen volumes and facilitate specialist consultations across institutions. Another important development is the growing need to preserve sufficient tissue for simultaneous morphological assessment and downstream molecular profiling.
• Diagnostic imaging supports cancer detection, anatomical localization, disease staging, biopsy guidance, and treatment-response assessment through technologies such as computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), mammography, and ultrasound. A distinctive characteristic of the U.S. market is the growing emphasis on integrating imaging findings with pathology and molecular diagnostic results to develop a more complete understanding of individual tumors. Advanced imaging protocols and AI-assisted image analysis can help radiologists identify suspicious lesions, prioritize cases for review, and improve consistency in image interpretation. Imaging also plays an important role in determining whether a suspicious abnormality requires further investigation and in guiding minimally invasive sampling procedures.
• The biopsy segment focuses on obtaining tissue or cellular material for the confirmation and characterization of suspected cancer. In the U.S. market, it includes needle-based sampling, image-guided biopsies, endoscopic procedures, surgical biopsies, and the associated instruments and specimen collection systems. Its distinctive market dynamic is the growing preference for minimally invasive approaches when clinically appropriate, helping clinicians obtain diagnostic material while limiting procedural burden. Image-guided biopsy techniques are particularly important when lesions are located deep within organs or cannot be reliably assessed through physical examination alone. At the same time, tissue biopsies remain essential for evaluating tumor architecture, confirming histological subtype, and supplying specimens for molecular testing.

USA Cancer Diagnostics By Application
• Breast cancer diagnostics in the United States are characterized by a well-established screening infrastructure combined with increasingly personalized diagnostic assessment. Mammography remains a central screening and diagnostic tool, while ultrasound and MRI provide additional evaluation in selected patients and clinical circumstances. Tissue biopsy and anatomic pathology are important for confirming malignancy and determining tumor characteristics, including hormone receptor expression and HER2 status. A distinctive feature of this application segment is the close integration of imaging findings with pathological biomarkers, allowing clinicians to distinguish tumors that may appear similar radiologically but require different treatment strategies. Digital breast tomosynthesis, image-guided biopsy, and advanced pathology methods support more detailed assessment of suspicious findings.
• The U.S. colorectal cancer diagnostics segment combines stool-based screening tests, colonoscopy, tissue biopsy, histopathological examination, and molecular testing to support detection and subsequent clinical management. A distinctive aspect of this segment is its dependence on a coordinated screening-to-confirmation pathway: noninvasive screening can identify individuals who require further investigation, while colonoscopy enables direct examination of the bowel, removal of certain precancerous lesions, and collection of tissue for pathological evaluation. Molecular profiling becomes particularly relevant after cancer confirmation, as tumor biomarkers can help guide treatment selection and identify patients who may benefit from specific targeted or immunotherapy approaches. Testing for mismatch repair deficiency and microsatellite instability is especially important in appropriate colorectal cancer cases, including assessment relevant to Lynch syndrome and treatment planning.
• Lung cancer diagnostics in the United States are increasingly shaped by the combination of imaging-based detection, tissue confirmation, and comprehensive molecular profiling. Low-dose CT screening is an important approach for eligible high-risk individuals, while diagnostic CT, PET imaging, bronchoscopy, and image-guided biopsy support the evaluation and characterization of suspicious lesions. A distinguishing feature of this segment is the need to obtain sufficient diagnostic material for both histological classification and molecular analysis, particularly in non-small cell lung cancer. Testing for actionable alterations, including EGFR mutations, ALK rearrangements, and other clinically relevant biomarkers, can determine whether targeted treatment options are appropriate. Comprehensive genomic profiling and selected liquid biopsy applications are therefore important components of the diagnostic pathway, especially when tissue is limited or repeat sampling presents difficulties.
• Prostate cancer diagnostics in the U.S. market involve a combination of prostate-specific antigen (PSA) testing, clinical risk assessment, multiparametric MRI, prostate biopsy, and pathological evaluation. A distinctive feature of this segment is the emphasis on differentiating clinically significant disease from slower-growing tumors that may be suitable for active surveillance rather than immediate treatment. Multiparametric MRI and MRI-targeted biopsy can help clinicians investigate suspicious lesions and improve the characterization of disease in appropriately selected patients. Pathology findings, including tumor grade and extent, remain central to risk stratification, while molecular and genomic assays may provide additional information in selected cases. The market also reflects ongoing efforts to reduce unnecessary biopsies and minimize the detection and overtreatment of indolent cancers without compromising the identification of aggressive disease.
• The other cancer applications segment encompasses diagnostic needs across conditions such as ovarian, cervical, pancreatic, liver, skin, thyroid, and hematological cancers, each requiring different combinations of screening, imaging, tissue sampling, and laboratory testing. A distinctive feature of this segment is its clinical diversity: diagnostic strategies must be tailored to tumor biology, anatomical location, disease presentation, and the availability of validated biomarkers. For example, cervical cancer diagnostics incorporate HPV testing and cytological assessment, while hematological malignancies frequently require specialized flow cytometry, immunophenotyping, and molecular or cytogenetic analysis. Ovarian and pancreatic cancer evaluation may rely on a combination of imaging, clinical assessment, tissue confirmation, and selected biomarker tests, whereas skin cancer diagnosis often depends on lesion examination and biopsy.

Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Cancer Diagnostics Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• Consumables and reagents
• Instruments

By Technology
• IVD testing
• Anatomic pathology
• Diagnostic imaging
• Biopsy

By Application
• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Prostate Cancer
• Others